181355-92-0Relevant articles and documents
Alkoxy pyridone compound as well as preparation method and application thereof
-
Paragraph 0265-0267, (2020/12/15)
The invention belongs to the field of medicinal chemistry, specifically, the invention relates to a series of inhibitors of factor XIa (FXIa for short) with a novel structure as well as a preparationmethod and an application thereof. The structure is shown as the following general formula (I). These compounds or stereoisomers, racemates, geometric isomers, tautomers, prodrugs, hydrates, solvatesor pharmaceutically acceptable salts and pharmaceutical compositions thereof can be used to treat or/and prevent related diseases mediated by factor XIa (FXIa for short).
HETEROARYLBENZIMIDAZOLE COMPOUNDS
-
Page/Page column 454, (2017/07/06)
The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.
Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
-
Page/Page column 36-37, (2012/12/13)
New pyridin-2(1h)-one derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
PYRIDIN-2 (1H) -ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES
-
Page/Page column 142-143, (2012/12/13)
Compoundshaving the chemical structure of formula (I) are disclosed; as well as process for theirpreparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS
-
Page/Page column 95, (2010/06/15)
Compounds of Formula (I) that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula (I), together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, ar
Metalation of diazines XVII. Very hindered bases as new metalating agents, improvement of regioselectivity for the metalation of 3-chloro-6-methoxypyridazine
Mojovic, Ljubica,Turck, Alain,Ple, Nelly,Dorsy, Muriel,Ndzi, Bruno,Queguiner, Guy
, p. 10417 - 10426 (2007/10/03)
The different factors governing the regioselectivity of the metalation of 3-chloro-6-methoxypyridazine with alkylamides were studied. Very hindered bases were used as new metalating agents and a very good regioselectivity was obtained.